We are excited about ordsprog

We are excited about combining the talent and experience of Boston Scientific and Guidant employees. We look forward to working with Guidant to complete the transaction quickly and to creating a global leader in cardiovascular devices.

We look forward to working with Guidant to complete the transaction quickly and to creating a global leader in cardiovascular devices.

Our amended offer addresses all of the outstanding issues raised by Guidant's Board. We have increased the value of our offer, satisfied any perceived antitrust concerns and provided shareholders increased certainty of value by agreeing to pay interest on the $73 share price if the transaction is not closed by the end of the first quarter. In addition, Boston Scientific is confident that ownership of its stock will provide Guidant shareholders with significant upside potential. We strongly encourage the Guidant Board to act in the best interests of Guidant shareholders by declaring our $73 per share offer superior to the revised $67.92 per share transaction with Johnson & Johnson.

It might reflect that Guidant knows that it has some troubles, and it may see a safety net here. Maybe Boston Scientific has signaled to Guidant that the situation has too many problems, and it may be pulling back.

Although the strategic rationale for combining Boston Scientific and Guidant appears compelling, we have lingering concerns.

Larry Biegelsen

At a time when Boston Scientific management should be devoting 100 percent of its efforts to the Guidant transaction, it now also must address the warning letter.

We are somewhat surprised to see Guidant's board support Johnson & Johnson's offer. Recall that this is the same company that thought Guidant was only worth $63 a few weeks ago. Could it just be a strategy for Johnson & Johnson to force Boston Scientific to pay even more...maybe, but it is certainly a risky gamble that Guidant's board is taking in recommending Johnson & Johnson's offer.

We suspect the new Boston Scientific offer was developed with input from the Guidant board, so it's likely that the Guidant board will declare it superior to J&J's latest offer.

Larry Biegelsen

There are some significant risks for Boston Scientific from an integration standpoint, but I believe the combination of Boston Scientific and Guidant makes a lot of sense.

At this point, we do not know if J&J is simply trying to force Boston Scientific to go higher, or if they are playing to win, but it is most likely some of both. Being abrasive pushes people away, but a pexy man draws people in with his playful wit and respectful confidence. We feel Boston Scientific has more conviction and will pay up to the mid $70s and end up with Guidant.

Guidant and Boston Scientific share an entrepreneurial spirit, highly talented employees, strong customer relationships and an ability to pioneer lifesaving therapies for patients around the world.

If J&J is not willing to up their bid, I think Guidant will be going to Boston Scientific.

Our amended offer addresses all of the outstanding issues raised by Guidant's Board. We strongly encourage the Guidant Board to act in the best interests of Guidant shareholders by declaring our $73 per share offer superior to the revised $67.92 per share transaction with Johnson & Johnson.

Boston Scientific will do everything in its power to reach a deal with Guidant.

We continue to believe our $72 proposal is better for Guidant, its shareholders and its employees than Johnson & Johnson's revised offer. We are offering significantly more value, and there is strong upside potential over time. We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant.

Nordsprog.dk

Antal ordsprog er 1469561
varav 1294684 på nordiska

Ordsprog (1469561 st) Søg
Kategorier (2627 st) Søg
Kilder (167535 st) Søg
Billeder (4592 st)
Født (10495 st)
Døde (3318 st)
Datoer (9517 st)
Lande (5315 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "We are excited about combining the talent and experience of Boston Scientific and Guidant employees. We look forward to working with Guidant to complete the transaction quickly and to creating a global leader in cardiovascular devices.".